oxo-pyridin-4-yl-acetic acid | 71708-14-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: oxo-pyridin-4-yl-acetic acid
• 英文别名: (4-Pyridyl)glyoxylic acid；pyridin-4-yl glyoxylic acid；4-Pyridyl glyoxylic acid；2-oxo-2-pyridin-4-ylacetic acid
• CAS: 71708-14-0
• 化学式: C₇H₅NO₃
• 分子量: 151.122
• InChiKey: FFHDNMFEVBACKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,6-Dimethoxy-11,17-diazatetracyclo[11.3.1.02,11.03,8]heptadeca-3(8),4,6-trien-12-one 、 oxo-pyridin-4-yl-acetic acid 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以0.14 g的产率得到1-{4,6-Dimethoxy-12-oxo-11,17-diazatetracyclo[11.3.1.0^{2,11}.0^{3,8}]heptadeca-3(8),4,6-trien-17-yl}-2-(pyridin-4-yl)ethane-1,2-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands

  摘要：

  Since the discovery that FK-506 promotes neurite outgrowth, considerable attention has been focused on the development of potent nonimmunosuppressive ligands for FK-506 binding proteins (FKBPs). Such neuroimmunophilin agents have been reported to show neuroregenerative activity in a variety of cell and animal models including neurite outgrowth, age-related cognitive decline, Parkinson's disease, peripheral nerve injury, optic nerve degeneration, and diabetic neuropathy. We have designed and synthesized a unique series of tetracyclic aza-amides that have been shown to be potent FKBP12 rotamase inhibitors. The structure-activity relationships established in this study have demonstrated diverse structural modifications that result in potent rotamase inhibitory activity.

  DOI：

  10.1021/jm049161u
• 作为产物：
  描述：

  (4-hydroxyphenylimino)pyridin-4-ylacetonitrile 在 盐酸 作用下， 以73%的产率得到oxo-pyridin-4-yl-acetic acid
  参考文献：
  名称：

  一种由杂环醛，对氨基苯酚和氰化钠制备杂环α-亚氨基腈和α-氧代乙酸的简便方法

  摘要：

  描述了非常有效，简单且高收率的方法，可将杂环醛转化为杂环亚甲基-对羟基苯胺，杂环α-亚甲基腈，最后转化为杂环α-氧代乙酸。考虑到这些化合物中的许多具有生物活性，使用易于获得的廉价原料优化了合成方法，并且产物的纯化仅涉及简单的结晶。

  DOI：

  10.1016/s0040-4039(02)00799-2

文献信息

• Tetracyclic spiro-hydantoin aldose reductase inhibitors and compositions
  申请人：Pfizer Inc.

  公开号：US04656169A1

  公开（公告）日：1987-04-07

  Novel biologically-active tetracyclic spiro-hydantoin derivatives which are potent inhibitors of aldose reductase and useful in treating diabetic complications are disclosed. Pharmaceutical compositions containing the novel compounds and a method of treating chronic diabetic complications are also disclosed. A preferred compound is 9'-chloro-5',6'-dihydro-2'-phenyl-spiro[imidazolidine-5,7'-7'H-pyrido(1,2, 3-de)quinoxaline]2,3',4-trione.

  揭示了一种新颖的具有生物活性的四环螺内酰脲衍生物，它们是醛糖还原酶的强效抑制剂，并且在治疗糖尿病并发症方面具有用途。还公开了含有这种新颖化合物的药物组合物以及治疗慢性糖尿病并发症的方法。一种首选化合物是9'-氯-5',6'-二氢-2'-苯基-螺[咪唑啉-5,7'-7'H-吡啶并(1,2,3-de)喹喔啉]2,3',4-三酮。
• A Facile Aerobic Copper-Catalyzed α-Oxygenation of Aryl Thioacetamides: An Efficient Access to α-Keto Aryl Thioamides
  作者：Firouz Moghaddam、Zohreh Mirjafary、Hamdollah Saeidian、Marjan Javan

  DOI：10.1055/s-2008-1042925

  日期：2008.4

  Copper(II) efficiently catalyzes the aerobic oxidation of aryl thioacetamides into the corresponding α-keto aryl thioamides in moderate to high yields in the presence of K2CO3 under O2 atmosphere. This protocol is simple, clean, and generates water as the only byproduct. A mechanism is proposed for the reaction course.

  铜(II)在O2气氛下，存在K2CO3的条件下，高效催化芳基硫代乙酰胺的好氧氧化，生成相应的α-酮芳基硫代胺，收率中等到高。本方法简单、干净，并且只生成水作为副产品。对此反应过程提出了一种机制。
• Synthesis and antitubercular activity of (4-pyridyl)glyoxylic acid
  作者：M. K. Nurullaeva、U. M. Azizov、V. A. Azimov、E. E. Mikhlina、R. A. Dubinskii、T. Ya. Filipenko、L. N. Filitis、O. Yu. Amel'kin、L. N. Yakhontov

  DOI：10.1007/bf00763664

  日期：1988.9
• TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
  申请人：SCHERING CORPORATION

  公开号：EP1021448B1

  公开（公告）日：2003-05-02
• NURULLAEVA, M. K.;AZIZOV, U. M.;AZIMOV, V. A.;MIXLINA, E. E.;DUBINSKIJ, R+, XIM.-FARMATS. ZH., 22,(1988) N 9, S. 1987-1091
  作者：NURULLAEVA, M. K.、AZIZOV, U. M.、AZIMOV, V. A.、MIXLINA, E. E.、DUBINSKIJ, R+

  DOI：——

  日期：——